Formulation and evaluation of coencapsulated rifampicin and isoniazid liposomes using different lipids

Roopa Karki, G. Subramanya, N. Udupa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

An attempt has been made to design suitable co encapsulated liposomal drug delivery system for rifampicin and isoniazid and for the evaluation of these systems in vitro and in vivo. A modified lipid layer hydration method was employed to prepare these vesicular carriers. The formulated systems were characterized for size distribution analysis, drug entrapment, drug release profiles and vesicular stability carried out. In vivo drug kinetics and histopathology study were carried out on normal healthy albino rats. For co encapsulated liposome of rifampicin and isoniazid various pharmacokinetic parameters were determined. Coencpsulated liposomal formulations elevated plasma elimination half life and decreased elimination rate constants for rifampicin and isoniazid, in vivo studies suggested that co encapsulation retard the release of drug from circulation compared to free drug due to slow drug release into systemic circulation. A three fold increase in the area under plasma rifampicin and isoniazid concentration-time curve for encapsulated drug. This formulation also reduces the accumulation of drug in the liver kidney and lungs. It is evident from this study that liposomes could be promising delivery systems for rifampicin and isoniazid with prolonged drug release profiles and reasonably good stability characteristics.

Original languageEnglish
Pages (from-to)177-188
Number of pages12
JournalActa Pharmaceutica Sciencia
Volume51
Issue number2
Publication statusPublished - 2009

Fingerprint

Isoniazid
Rifampin
Liposomes
Lipids
Pharmaceutical Preparations
Pharmacokinetics
Drug Delivery Systems
Half-Life
Kidney
Lung
Drug Liberation
Liver

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{c4e69e1511944dd5b7b839b2a8a717ab,
title = "Formulation and evaluation of coencapsulated rifampicin and isoniazid liposomes using different lipids",
abstract = "An attempt has been made to design suitable co encapsulated liposomal drug delivery system for rifampicin and isoniazid and for the evaluation of these systems in vitro and in vivo. A modified lipid layer hydration method was employed to prepare these vesicular carriers. The formulated systems were characterized for size distribution analysis, drug entrapment, drug release profiles and vesicular stability carried out. In vivo drug kinetics and histopathology study were carried out on normal healthy albino rats. For co encapsulated liposome of rifampicin and isoniazid various pharmacokinetic parameters were determined. Coencpsulated liposomal formulations elevated plasma elimination half life and decreased elimination rate constants for rifampicin and isoniazid, in vivo studies suggested that co encapsulation retard the release of drug from circulation compared to free drug due to slow drug release into systemic circulation. A three fold increase in the area under plasma rifampicin and isoniazid concentration-time curve for encapsulated drug. This formulation also reduces the accumulation of drug in the liver kidney and lungs. It is evident from this study that liposomes could be promising delivery systems for rifampicin and isoniazid with prolonged drug release profiles and reasonably good stability characteristics.",
author = "Roopa Karki and G. Subramanya and N. Udupa",
year = "2009",
language = "English",
volume = "51",
pages = "177--188",
journal = "Acta Pharmaceutica Sciencia",
issn = "1307-2080",
publisher = "University of Istanbul",
number = "2",

}

Formulation and evaluation of coencapsulated rifampicin and isoniazid liposomes using different lipids. / Karki, Roopa; Subramanya, G.; Udupa, N.

In: Acta Pharmaceutica Sciencia, Vol. 51, No. 2, 2009, p. 177-188.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Formulation and evaluation of coencapsulated rifampicin and isoniazid liposomes using different lipids

AU - Karki, Roopa

AU - Subramanya, G.

AU - Udupa, N.

PY - 2009

Y1 - 2009

N2 - An attempt has been made to design suitable co encapsulated liposomal drug delivery system for rifampicin and isoniazid and for the evaluation of these systems in vitro and in vivo. A modified lipid layer hydration method was employed to prepare these vesicular carriers. The formulated systems were characterized for size distribution analysis, drug entrapment, drug release profiles and vesicular stability carried out. In vivo drug kinetics and histopathology study were carried out on normal healthy albino rats. For co encapsulated liposome of rifampicin and isoniazid various pharmacokinetic parameters were determined. Coencpsulated liposomal formulations elevated plasma elimination half life and decreased elimination rate constants for rifampicin and isoniazid, in vivo studies suggested that co encapsulation retard the release of drug from circulation compared to free drug due to slow drug release into systemic circulation. A three fold increase in the area under plasma rifampicin and isoniazid concentration-time curve for encapsulated drug. This formulation also reduces the accumulation of drug in the liver kidney and lungs. It is evident from this study that liposomes could be promising delivery systems for rifampicin and isoniazid with prolonged drug release profiles and reasonably good stability characteristics.

AB - An attempt has been made to design suitable co encapsulated liposomal drug delivery system for rifampicin and isoniazid and for the evaluation of these systems in vitro and in vivo. A modified lipid layer hydration method was employed to prepare these vesicular carriers. The formulated systems were characterized for size distribution analysis, drug entrapment, drug release profiles and vesicular stability carried out. In vivo drug kinetics and histopathology study were carried out on normal healthy albino rats. For co encapsulated liposome of rifampicin and isoniazid various pharmacokinetic parameters were determined. Coencpsulated liposomal formulations elevated plasma elimination half life and decreased elimination rate constants for rifampicin and isoniazid, in vivo studies suggested that co encapsulation retard the release of drug from circulation compared to free drug due to slow drug release into systemic circulation. A three fold increase in the area under plasma rifampicin and isoniazid concentration-time curve for encapsulated drug. This formulation also reduces the accumulation of drug in the liver kidney and lungs. It is evident from this study that liposomes could be promising delivery systems for rifampicin and isoniazid with prolonged drug release profiles and reasonably good stability characteristics.

UR - http://www.scopus.com/inward/record.url?scp=70349705770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349705770&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 177

EP - 188

JO - Acta Pharmaceutica Sciencia

JF - Acta Pharmaceutica Sciencia

SN - 1307-2080

IS - 2

ER -